isn't the rationale of any new class of antiviral related to potency and/or resistance?
It's clearly a very broad, if not obvious, statement. ACHN is being very cryptic about this upcoming HCV class, presumably for competitive reasons. I wonder if this is in part because it's a class outside the normal classes of PIs, nukes, and non-nukes.
Market Data 
Markets 
AI
